Smaller lytic anticancer peptides evaded the heparan sulfate barrier on cancer cell surfaces that inhibited larger peptides — size optimization enables effective cancer cell membrane disruption despite surface shielding.
Key findingSmaller lytic anticancer peptides evaded the heparan sulfate barrier on cancer cell surfaces that inhibited larger peptides — size optimization enable
What the researchers found
Smaller lytic anticancer peptides evaded the heparan sulfate barrier on cancer cell surfaces that inhibited larger peptides — size optimization enables effective cancer cell membrane disruption despite surface shielding.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2011.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
Small lytic peptides escape the inhibitory effect of heparan sulfate on the surface of cancer cells.
BMC cancer, 11, 116
Citation
Fadnes, Bodil; Uhlin-Hansen, Lars; Lindin, Inger; Rekdal, Øystein. (2011). Small lytic peptides escape the inhibitory effect of heparan sulfate on the surface of cancer cells.. BMC cancer, 11, 116. https://doi.org/10.1186/1471-2407-11-116